Birchview Capital, LP

In its 13F for Q2 2024 (holdings as of June 30, 2024, filed June 30, 2025), Birchview Capital, LP reported 60 stock positions worth $108.2 million. Its top holding was Bristol-Myers Squibb (BMY) at 26.4% of the portfolio, followed by Biodesix (BDSX, 8.0%) and Elutia (ELUT, 7.1%). Compared with Q1 2024, it opened 3 new positions, sold out of 2, added to 7 and reduced 9. The biggest buy was Biodesix (BDSX, shares +7%) and the biggest sale Bristol-Myers Squibb (BMY, shares −2%).

Most Recent 13F
Q2 2026
Location
BURLINGTON, VT
CIK
0001618205
Portfolio Value
$108.2M (Q2 2024)
SEC Filing
0001618205-25-000006 ↗ filed Jun 30, 2025

Holdings Value

0$50.0M$100.0M$150.0M$200.0M$250.0M Q1 2024: $122.7M Q1 2024 Q2 2024: $108.2M $108.2M Q2 2024 Q3 2024: $115.5M Q3 2024 Q4 2024: $122.9M Q4 2024 Q1 2025: $115.2M Q1 2025 Q2 2025: $100.7M Q2 2025 Q3 2025: $132.4M Q3 2025 Q4 2025: $170.8M Q4 2025 Q1 2026: $175.7M Q1 2026 Q2 2026: $213.8M Q2 2026

Holdings 60 stocks · $108.2M
BMY Bristol-Myers Squibb Co. 26.42% 688,218 $28.6M Reduce -2.2%
BDSX Biodesix Inc. 8.04% 5,696,113 $8.7M Add +6.5%
ELUT Elutia Inc. 7.11% 1,551,655 $7.7M Reduce -6.3%
NBIX Neurocrine Biosciences Inc. 5.37% 42,240 $5.8M Reduce -45.3%
SILK Silk Road Medical Inc. filed as SILK RD MED INC 3.95% 158,094 $4.3M No change
PRTA Prothena Corp. PLC 3.88% 203,574 $4.2M Add +20.1%
ACAD Acadia Pharmaceuticals Inc. 3.76% 250,400 $4.1M No change
OVV Ovintiv Inc. 3.21% 74,200 $3.5M Reduce -11.9%
UTHR United Therapeutics Corp. 2.94% 10,000 $3.2M Reduce -9.1%
HROW Harrow Inc. 2.90% 150,000 $3.1M No change
STOK Stoke Therapeutics Inc. 2.62% 210,000 $2.8M No change
PHR Phreesia Inc. 2.25% 114,700 $2.4M No change
CORT Corcept Therapeutics Inc. 2.22% 74,000 $2.4M Add +48.0%
QDEL Quidelortho Corp. 2.08% 67,619 $2.2M Add +3.7%
MASI Masimo Corp. 1.78% 15,280 $1.9M No change
FHTX Foghorn Therapeutics Inc. 1.71% 320,930 $1.8M No change
ETRN Equitrans Midstream Corp. 1.60% 133,050 $1.7M No change
PTGX Protagonist Therapeutics Inc. 1.54% 48,000 $1.7M No change
AXGN Axogen Inc. 1.32% 197,000 $1.4M Add +13.9%
DCGO Docgo Inc. 1.31% 460,000 $1.4M No change
ALKS Alkermes PLC 1.11% 50,000 $1.2M No change
TVTX Travere Therapeutics Inc. 0.93% 122,000 $1.0M No change
ATEC Alphatec Holdings Inc. 0.85% 88,000 $920K No change
CSTL Castle Biosciences Inc. 0.68% 34,000 $740K Add +142.9%
XOM Exxon Mobil Corp. 0.62% 5,849 $673K New
PGNY Progyny Inc. 0.58% 22,000 $629K No change
TXG 10X Genomics Inc. Class A 0.54% 30,000 $584K No change
KNSA Kiniksa Pharmaceuticals Ltd. 0.52% 30,000 $560K No change
KALV Kalvista Pharmaceuticals Inc. 0.50% 46,000 $542K No change
CYTK Cytokinetics Inc. 0.50% 10,000 $542K No change
APLS Apellis Pharmaceuticals Inc. 0.50% 14,000 $537K Reduce -22.2%
HALO Halozyme Therapeutics Inc. 0.48% 10,000 $524K No change
CHRS Coherus Oncology Inc. 0.43% 270,000 $467K No change
KPTI Karyopharm Therapeutics Inc. 0.38% 469,832 $408K No change
ARVN Arvinas Inc. 0.37% 15,000 $399K No change
SRPT Sarepta Therapeutics Inc. 0.37% 2,500 $395K No change
XENE Xenon Pharmaceuticals Inc. 0.36% 10,000 $390K No change
ACCELERATE DIAGNOSTICS INC 0.35% 325,239 $381K No change
SWTX Springworks Therapeutics Inc. 0.35% 10,000 $377K No change
CGEM Cullinan Therapeutics Inc. 0.32% 20,000 $349K Reduce -20.4%
NVCR Novocure Ltd. 0.32% 20,000 $343K New
AXSM Axsome Therapeutics Inc. 0.30% 4,000 $322K No change
KROS Keros Therapeutics Inc. 0.30% 7,000 $320K No change
BLUEBIRD BIO INC 0.28% 311,200 $306K Reduce -3.1%
FOLD Amicus Therapeutics Inc. 0.26% 28,000 $278K No change
BIOHAVEN PHARMACEUTICAL HOLD 0.24% 7,365 $256K No change
BCRX Biocryst Pharmaceuticals Inc. 0.23% 40,000 $247K Add +100.0%
XNCR Xencor Inc. 0.22% 12,300 $233K No change
WVE Wave Life Sciences Ltd. 0.18% 40,000 $200K No change
GTHX G1 Therapeutics Inc. 0.17% 80,000 $182K No change
INBX Inhibrx Biosciences Inc. 0.16% 12,110 $171K No change
GOSS Gossamer Bio Inc. 0.12% 138,176 $124K No change
LQDA Liquidia Corp. 0.11% 10,000 $120K No change
IFRX Inflarx NV 0.08% 50,000 $87K No change
CABA Cabaletta Bio Inc. 0.07% 10,000 $75K No change
TSVT 2SEVENTY Bio Inc. 0.06% 17,833 $69K Reduce -10.1%
VTYX Ventyx Biosciences Inc. 0.06% 28,800 $67K No change
ZNTL Zentalis Pharmaceuticals Inc. 0.06% 16,000 $65K No change
OM Outset Medical Inc. 0.04% 10,000 $39K New
CERO THERAPEUTICS HLDGS INC 0.00% 12,972 $4K No change

Portfolio Sells Q1 2024 → Q2 2024
BMY Bristol-Myers Squibb Co. Reduce -2.2% 26.42% −4.68
NBIX Neurocrine Biosciences Inc. Reduce -45.3% 5.37% −3.31
PXD Pioneer Natural Resources Co. Sold out 0.00% −0.81
APLS Apellis Pharmaceuticals Inc. Reduce -22.2% 0.50% −0.37
OVV Ovintiv Inc. Reduce -11.9% 3.21% −0.35
BLUEBIRD BIO INC Reduce -3.1% 0.28% −0.05
CGEM Cullinan Therapeutics Inc. Reduce -20.4% 0.32% −0.03
TSVT 2SEVENTY Bio Inc. Reduce -10.1% 0.06% −0.02
YIELD10 BIOSCIENCE INC Sold out 0.00% −0.01
UTHR United Therapeutics Corp. Reduce -9.1% 2.94% +0.88
ELUT Elutia Inc. Reduce -6.3% 7.11% +2.86

Portfolio Buys Q1 2024 → Q2 2024
BDSX Biodesix Inc. Add +6.5% 8.04% +1.82
CORT Corcept Therapeutics Inc. Add +48.0% 2.22% +1.20
XOM Exxon Mobil Corp. New 0.62% +0.62
PRTA Prothena Corp. PLC Add +20.1% 3.88% +0.46
CSTL Castle Biosciences Inc. Add +142.9% 0.68% +0.43
NVCR Novocure Ltd. New 0.32% +0.32
AXGN Axogen Inc. Add +13.9% 1.32% +0.18
BCRX Biocryst Pharmaceuticals Inc. Add +100.0% 0.23% +0.15
OM Outset Medical Inc. New 0.04% +0.04
QDEL Quidelortho Corp. Add +3.7% 2.08% −0.47

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 72$213.8MKLAC, BMY, LRCX, NTLA, SLDB
Q1 2026 73$175.7MKLAC, BMY, CMPX, LRCX, STOK
Q4 2025 68$170.8MKLAC, BMY, CMPX, STOK, LRCX
Q3 2025 69$132.4MKLAC, BMY, CORT, PRTA, STOK
Q2 2025 71$100.7MBMY, KLAC, CORT, OVV, ACAD
Q1 2025 68$115.2MBMY, CORT, ACAD, PRTA, BDSX
Q4 2024Amended 68$122.9MBMY, BDSX, ACAD, ELUT, PRTA
Q3 2024Amended 61$115.5MBMY, BDSX, ACAD, ELUT, UTHR
Q2 2024Amended 60$108.2MBMY, BDSX, ELUT, NBIX, SILK
Q1 2024Amended 59$122.7MBMY, NBIX, BDSX, ELUT, ACAD